Literature DB >> 1888633

COMT inhibition with nitecapone does not affect the tyramine pressor response.

S Sundberg1, A Gordin.   

Abstract

Nitecapone (OR-462) is a new selective COMT inhibitor with gastroprotective properties. The aim of the present study was to determine whether nitecapone potentiates the haemodynamic effects of a tyramine-induced increase in catecholamine release. The systolic blood pressure response to tyramine was studied in 11 healthy male volunteers (age 20-32 years). Tyramine was given i.v. as rapid bolus injections in increasing doses without drug intake and after oral intake of single doses of 25 mg and 100 mg of nitecapone. The tyramine dose required to increase systolic blood pressure by 30 mm Hg ('pressor dose') was 4.98 mg, 5.04 mg and 4.88 mg after no medication, and with 25 mg and 100 mg of nitecapone, respectively. There were also no differences in the systolic blood pressure response vs time curves between the three regimens. COMT inhibition with nitecapone did not potentiate the haemodynamic responses to tyramine-induced catecholamine release.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888633      PMCID: PMC1368506          DOI: 10.1111/j.1365-2125.1991.tb05626.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  The mode of action of tyramine.

Authors:  M J DAVEY; J B FARMER
Journal:  J Pharm Pharmacol       Date:  1963-03       Impact factor: 3.765

2.  Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.

Authors:  A Korn; M Da Prada; W Raffesberg; S Gasic; H G Eichler
Journal:  J Cardiovasc Pharmacol       Date:  1988-01       Impact factor: 3.105

3.  Evaluation of methods of administering tyramine to raise systolic blood pressure.

Authors:  D G Pace; S B Reele; L M Rozik; C A Rogers-Phillips; J A Dabice; S V Givens
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

4.  Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.

Authors:  S Sundberg; M Scheinin; P Ojala-Karlsson; S Kaakkola; J Akkila; A Gordin
Journal:  Clin Pharmacol Ther       Date:  1990-10       Impact factor: 6.875

5.  Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.

Authors:  E Nissinen; I B Lindén; E Schultz; S Kaakkola; P T Männistö; P Pohto
Journal:  Eur J Pharmacol       Date:  1988-08-24       Impact factor: 4.432

6.  Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.

Authors:  D Pickar; R M Cohen; D C Jimerson; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Beta-blockade antagonism of tyramine-induced rise in blood pressure.

Authors:  F Colombo; R Sega; F Mailland; R Rigo; L Palvarini; A Libretti
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  7 in total
  3 in total

1.  Effect of oral linezolid on the pressor response to intravenous tyramine.

Authors:  Mireille V Cantarini; Catherine J Painter; Elaine M Gilmore; Catherine Bolger; Claire L Watkins; Andrew M Hughes
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

2.  Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.

Authors:  P T Ménnistó
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

3.  The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.

Authors:  S Sundberg; M Scheinin; P Ojala-Karlsson; J Akkila; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.